Powered by: Motilal Oswal
2024-10-07 09:52:01 am | Source: Accord Fintech
Dr. Reddy`s Laboratories rises as its arm incorporates new wholly-owned subsidiary

Dr. Reddy's Laboratories is currently trading at Rs. 6704.20, up by 68.70 points or 1.04% from its previous closing of Rs. 6635.50 on the BSE.

The scrip opened at Rs. 6670.00 and has touched a high and low of Rs. 6708.50 and Rs. 6640.00 respectively. So far 1375 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 7101.00 on 21-Aug-2024 and a 52 week low of Rs. 5212.10 on 30-Oct-2023.

Last one week high and low of the scrip stood at Rs. 6796.60 and Rs. 6613.35 respectively. The current market cap of the company is Rs. 110731.20 crore.

The promoters holding in the company stood at 26.65%, while Institutions and Non-Institutions held 48.41% and 10.36% respectively.

Dr. Reddy's Laboratories’ wholly owned subsidiary -- Dr. Reddy’s Laboratories SA, Switzerland, (DRSA) has incorporated a new wholly-owned subsidiary in Denmark, named ‘Dr. Reddy's Denmark ApS’ on October 4, 2024. Accordingly, Dr. Reddy's Denmark ApS is a step-down wholly-owned subsidiary of the company. The business of the Dr. Reddy's Denmark ApS is in line with the main line of business of the Company.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here